Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

15/04/2025 Eastern Time in USA The Dow Jones Industrial Average dropped by 0.38%, closing at 40368.96 points; the Nasdaq Composite dropped by 0.05%, closing at 16823.17 points; the S&P 500 Index dropped by 0.17%, closing at 5396.63 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

Ivanhoe Electric Inc.: Overnight gain 28.3%, Secures potential debt financing for copper project, boosting investor confidence and stock price

Ivanhoe Electric Inc., a U.S.-based mineral exploration and development firm, was incorporated in Delaware on July 14, 2020. The company focuses on advancing mineral deposits primarily within the United States, with the strategic objective of bolstering domestic supply chain independence and providing critical metal resources for the nation's economic electrification initiatives. As a wholly-owned subsidiary of High Power Exploration Inc., Ivanhoe Electric Inc.'s operational focus aligns with the strategic imperatives of developing domestic mineral resources in the United States. The company's mission is to identify, explore, and develop mineral deposits that are crucial for supporting the country's transition to a more electrified economy while reducing reliance on foreign mineral sources. By concentrating on U.S.-based projects, Ivanhoe Electric Inc. is positioning itself as a key player in the domestic critical minerals sector, addressing growing concerns about supply chain security and the increasing demand for metals essential to green technologies and advanced manufacturing processes.

Ivanhoe Electric Inc. (IE) experienced a significant stock price surge following the announcement of potential debt financing support of up to $825 million from the U.S. Export-Import Bank. This funding is earmarked for the development of the Santa Cruz copper project in Arizona, aligning with the U.S. "Make More in America" initiative aimed at bolstering critical mineral supply and enhancing national security. The company plans to submit a preliminary feasibility study for the project in June, with construction expected to commence in the first half of 2026. This substantial financial backing and clear project timeline have considerably boosted investor confidence, driving IE's stock up 28.3% on the day of the announcement. However, the stock remains down 14.2% year-to-date, despite this positive development.

Rezolve AI Ltd Ordinary Shares: Overnight gain 21.9%, Major contract with Mexican retailer boosts investor confidence, signaling potential turnaround despite yearly decline.

Rezolve AI Ltd, a pioneer in the mobile commerce sector, is revolutionizing consumer engagement through its cutting-edge artificial intelligence and machine learning-driven platform. The company's innovative technology seamlessly connects retailers, brands, and manufacturers with consumers across mobile and desktop devices, redefining the landscape of mobile interaction. The firm's state-of-the-art AI platform streamlines the purchasing process, offering users a one-touch solution for information retrieval and transaction execution. This advanced system not only enhances the consumer experience but also provides merchants with a scalable solution to effectively engage customers, manage high-volume traffic, and collect real-time engagement data. Rezolve AI's robust platform is poised to drive innovation in digital commerce, offering businesses powerful tools to thrive in an increasingly mobile-centric marketplace. By leveraging AI and machine learning capabilities, the company is at the forefront of transforming how businesses interact with consumers in the digital age. As Rezolve AI continues to expand its presence in the mobile commerce arena, investors and industry observers are closely watching its potential to disrupt traditional retail models and accelerate the adoption of AI-driven engagement strategies across various sectors.

Rezolve AI Ltd Ordinary Shares (RZLV) experienced a significant stock price surge following the announcement of a landmark $9.8 million annual contract with Liverpool, a prominent Mexican department store chain. This multi-year agreement underscores Liverpool's strong endorsement of Rezolve AI's innovative Brain Commerce technology stack. The contract notably includes the cutting-edge SEO Studio, deeply integrated with the Google ecosystem, highlighting Rezolve AI's strategic partnership with the tech giant. This collaboration not only solidifies Rezolve AI's position as a leader in AI-driven mobile commerce solutions but also promises substantial revenue growth. Despite RZLV's 63.6% year-to-date decline, investors view this major contract as a potential inflection point for the company's operations. The news catalyzed a remarkable 21.9% single-day stock price increase, rekindling investor confidence in Rezolve AI's future prospects.

Verve Therapeutics: Overnight gain 20.6%, Positive clinical results and FDA fast track boost investor confidence, driving stock surge

Verve Therapeutics, Inc. (NASDAQ: VERV) is a cutting-edge biotechnology firm specializing in the development of gene-editing therapies for cardiovascular diseases (CVD). The company's innovative approach focuses on creating single-course gene editing treatments, aiming to revolutionize CVD management by shifting from chronic care to a one-time curative intervention. The firm's groundbreaking platform has the potential to offer lifelong, substantial health benefits for patients with atherosclerotic cardiovascular disease (ASCVD) or those at high risk. This paradigm-shifting strategy could fundamentally transform the landscape of cardiovascular disease treatment, potentially disrupting traditional therapeutic modalities. Verve Therapeutics' novel approach underscores the growing importance of gene editing technologies in addressing complex, chronic diseases. As the company advances its pipeline, investors and healthcare professionals alike are closely monitoring its progress, recognizing the potential for significant market impact and improved patient outcomes in the cardiovascular space.

Verve Therapeutics (VERV) has experienced a significant stock price surge due to multiple factors. The company's VERVE-102 demonstrated positive results in the Heart-2 Phase 1b clinical trial, showing substantial LDL-C reduction and favorable safety profile, bolstering investor confidence. Additionally, the FDA granted Fast Track designation to VERVE-102, expediting its development process. Several investment firms, including HC Wainwright, Canaccord Genuity, and Guggenheim, raised their price targets for Verve Therapeutics (VERV) while maintaining buy ratings. The company's impressive 154.28% revenue growth over the past three months, far exceeding industry averages, coupled with a low debt-to-equity ratio, indicates robust financial health. These combined factors have contributed to the substantial appreciation in Verve Therapeutics (VERV) stock price, attracting increased investor interest in the gene editing therapeutics sector.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team.